EP
TGTX icon

Eudaimonia Partners’s TG Therapeutics TGTX Stock Holding History

Eudaimonia Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-904
Closed -$44K – 1264
2021
Q1 		$44K Buy
904
+438
+94% +$21K 0.01% 684
2020
Q4 		$24K Buy
+466
New +$15.7K 0.01% 811

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Eudaimonia Partners's TGTX Position: Q2 2021 in Review

Eudaimonia Partners sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 904 shares — an estimated $44K sold.

Eudaimonia Partners first reported a position in TGTX in Q4 2020 and held it in 2 quarters. The position peaked at $44K in Q1 2021. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • Eudaimonia Partners reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 904 TG Therapeutics shares in Q2 2021, an estimated $44K.
  • Eudaimonia Partners first reported a position in TG Therapeutics in Q4 2020 and held it in 2 quarters.
  • Eudaimonia Partners's TG Therapeutics position peaked at $44K in Q1 2021.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.